Abstract:As a key component in combination therapy for acquired immunodeficiency syndrome (AIDS), non-nucleoside reverse transcriptase inhibitors (NNRTIs) have been proven to be an essential way in stopping HIV-1 replication. In the present work, in silico studies were conducted on a series of 119 NNRTIs, including 1-(2-hydroxyethoxymethyl)-6-(phenylthio)thymine (HEPT) and dihydroalkoxybenzyloxopyrimidine (DABO) derivatives by using the comparative molecular field analysis (CoMFA), comparative molecular similarity indices analysis (CoMSIA), docking simulations and molecular dynamics (MD). The statistical results of the optimal model, the ligand-based CoMSIA one (Q 2 = 0.48, R ncv 2 =0.847, R pre 2 = 0.745) validates its satisfactory predictive capacity both internally and externally. The contour maps, docking and MD results correlate well with each other, drawing conclusions as follows: 1) Compounds with bulky substituents in position-6 of ring A, hydrophobic groups around position- 1, 2, 6 are preferable to the biological activities; 2) Two hydrogen bonds between RT inhibitor and the Tyr 318, Lys 101 residues, respectively, and a π-π bond between the inhibitor and Trp 188 are formed and crucial to the orientation of the active conformation of the molecules; 3) The binding pocket is essentially hydrophobic, which are determined by residues such as Trp 229, Tyr 318, Val 179, Tyr 188 and Val 108, and hydrophobic substituents may bring an improvement to the biological activity; 4) DABO and HEPT derivatives have different structures but take a similar mechanism to inhibit RT. The potency difference between two isomers in HEPTs can be explained by the distinct locations of the 6-naphthylmethyl substituent and the reasons are explained in details. All these results could be employed to alter the structural scaffold in order to develop new HIV-1 RT inhibitors that have an improved biological property. To the best of our knowledge, this is the first report on 3D-QSAR modeling of this series of HEPT and DABO NNRTs. The QSAR model and the information derived, we hope, will be of great help in presenting clear guidelines and accurate activity predictions for newly designed HIV-1 reverse transcriptase (RT) inhibitor.

Revealing The Drug-Resistant Mechanism For Diarylpyrimidine Analogue Inhibitors Of Hiv-1 Reverse Transcriptase

Drug Resistant Mechanism of Diaryltriazine Analog Inhibitors of HIV‐1 Reverse Transcriptase Using Molecular Dynamics Simulation and 3D‐QSAR

Discovery of Novel Diarylpyrimidines As Potent HIV-1 NNRTIs by Investigating the Chemical Space of a Less Explored "hydrophobic Channel"

Identification of Novel Diarylpyrimidines As Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors by Exploring the Primer Grip Region

Discovery of Novel Diarylpyrimidines As Potent HIV NNRTIs Via a Structure-Guided Core-Refining Approach

Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses

Design, Synthesis and Anti-Hiv Evaluation of Novel Diarylpyridine Derivatives As Potent HIV-1 NNRTIs.

Theoretical Study on Anti-mutant HIV-1 Virus Activity of Diaryltriazine Analogs

Docking, Molecular Dynamics and Quantitative Structure-Activity Relationship Studies for HEPTs and DABOs As HIV-1 Reverse Transcriptase Inhibitors

Druggability Modification Strategies of the Diarylpyrimidine‐type Non‐nucleoside Reverse Transcriptase Inhibitors

Three dimensional quantitative structure-activity relationship of DATA analogues as HIV-1 reverse transcriptase inhibitors

Identification of Dihydrofuro[3,4- D]pyrimidine Derivatives As Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.

Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors

Recent Advances in DAPYs and Related Analogues As HIV-1 NNRTIs.

Synthesis and Biological Evaluation of CHX-DAPYs As HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

Exploiting the Tolerant Region I of Non-nucleoside Reverse Transcriptase Inhibitor Binding Pocket (NNIBP): Discovery of Potent Diarylpyrimidine (DAPY)-typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.

QSAR studies for diarylpyrimidines against HIV-1 reverse transcriptase wild-type and mutant strains.

Chemical space exploration of novel naphthyl-carboxamide-diarylpyrimidine derivatives with potent anti-HIV-1 activity

3D-QSAR, Molecular Docking, and Molecular Dynamics Simulation of a Novel Thieno[3,4-D]pyrimidine Inhibitor Targeting Human Immunodeficiency Virus Type 1 Reverse Transcriptase

Follow On-Based Optimization of the Biphenyl-Dapys As HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors Against the Wild-Type and Mutant Strains.

Design and Optimization of Piperidine-Substituted Thiophene[3,2-D]pyrimidine-based HIV-1 NNRTIs with Improved Drug Resistance and Pharmacokinetic Profiles